SUBSCRIBERS

Drug developer Cennerv lodges prospectus for Catalist IPO

It specialises in treatments for depression, insomnia, dementia and autism

Sat, Sep 22, 2018 - 5:50 AM

Singapore

SINGAPORE-based biotech Cennerv Pharmaceuticals, a developer of drugs to treat central nervous system (CNS) disorders, lodged a preliminary prospectus on Wednesday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist...

To continue reading

for full content

if you are a subscriber

Get our introductory offer at only

$0 .99*/month

Cancel anytime

*$0.99/month for first 3 months

$29.90/month for the next 9 months

Need help?

CALL +65 6388 3838 EMAIL btocs@sph.com.sg

OPERATING HOURS (+8 GMT) MON-FRI: 8:30AM-5:30PM

Register to read this article. Log in if you are already a subscriber. Register to read this article. Log in if you are already a subscriber. Please log in or subscribe to continue reading.